Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation [7]

Canadian Journal of Anesthesia

Volumn 50, Issue 7, 2003, Pages 753-

  Ogata, Junichi ^a   Okamoto, Takashi ^a   Minami, Kouichiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; LANDIOLOL; PROPRANOLOL; VERAPAMIL;

AGED; ANESTHESIA INDUCTION; ASTHMA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CASE REPORT; CHOLECYSTECTOMY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; GENERAL ANESTHESIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; LETTER; MALE; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; TACHYCARDIA;

EID: 0142180168     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03018726     Document Type: Letter

References (3)

1. Atarashi H, Kuruma A, Yashima M, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther 2000; 68: 143-50.
2. Muraki K, Nakagawa H, Nagano N, et al. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle. J Pharmacol Exp Ther 1996; 278: 555-63.
3. Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo) 1992; 40: 1462-9.